Celldex’s cash runway extends into 2027, but potential delays or hurdles could necessitate earlier fundraising, exerting ...

Galderma has kicked off an ad campaign to show how its Nemluvio can empower people to rule over itchy eczema. Aiming to grow ...

SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.

On Tuesday morning, Galderma launched its Scratch Resistance campaign to highlight one of the most difficult symptoms of atopic dermatitis: nonstop itching. The campaign’s ad spot features atopic ...

to treat adults with prurigo nodularis. It is not known if NEMLUVIO is safe and effective in children with prurigo nodularis under 18 years of age. Do not take NEMLUVIO if you are allergic to ...

The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) for chronic ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch.